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Abstract: As vascular calcification is common in kidney transplant candidates, aorto-iliac vessel
imaging is performed for surgical planning. The aim of the present study was to investigate whether
a novel non-contrast enhanced computed tomography-based quantification technique for aorto-iliac
calcification can be used for cardiovascular risk stratification prior to kidney transplantation. In this
dual-center cohort study, we measured the aorto-iliac calcium score (CaScore) of 547 patients within
three years prior to transplantation (2005–2018). During a median (interquartile range) follow-up of
3.1 (1.4, 5.2) years after transplantation, 80 (14.7%) patients died, of which 32 (40.0%) died due to
cardiovascular causes, and 84 (15.5%) patients had a cardiovascular event. Kaplan-Meier survival
curves showed significant differences between the CaScore tertiles for cumulative overall-survival
(Log-rank test p < 0.0001), cardiovascular survival (p < 0.0001), and cardiovascular event-free survival
(p < 0.001). In multivariable Cox regression, the aorto-iliac CaScore was associated with all-cause
mortality (hazard ratio 1.53, 95%CI 1.14–2.06, p = 0.005), cardiovascular mortality (2.04, 1.20–3.45,
p = 0.008), and cardiovascular events (1.35, 1.01–1.80, p = 0.042). These independent associations of
the aorto-iliac CaScore with the outcome measures can improve the identification of patients at risk
for (cardiovascular) death and those who could potentially benefit from stringent cardiovascular
monitoring to improve their prognosis after transplantation.
Keywords: kidney transplantation; vascular calcification; aorta; iliac artery; cardiovascular diseases
1. Introduction
Kidney transplantation improves survival of patients with end-stage renal disease (ESRD) and
reduces cardiovascular disease burden [1,2]. Despite the improved prognosis after transplantation,
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patients remain vulnerable, with cardiovascular disease as the leading cause of death [2,3]. A high
overall prevalence of cardiovascular disease in the first year after kidney transplantation is reported,
with myocardial infarction (MI) in 5.1%, cerebrovascular accident (CVA)/transient ischemic attack
(TIA) in 7.3%, and peripheral artery disease (PAD) in 15.8% of patients [2,4].
Multidisciplinary evaluation, including consultation of a vascular surgeon, to evaluate the
cardiovascular status of kidney transplant candidates could improve the identification of patients at
risk for (cardiovascular) death and those who could potentially benefit from interventions to improve
their prognosis after transplantation [5–7]. When screening kidney transplant candidates, evaluation
generally includes traditional risk factors, as used in risk prediction scores for the general population
(i.e., the Framingham score), and transplant candidate-specific risk factors, with among others chronic
kidney disease–mineral bone disorder (CKD-MBD) [8,9]. As ESRD accelerates vascular calcification
and kidney transplantation incompletely decreases this acceleration, cardiovascular risk stratification
is not always straightforward in this population [10,11].
Prior studies have identified imaging-proven vascular calcification as a prognostic factor for
inferior survival and cardiovascular events in kidney transplant recipients [12,13]. For the applied
imaging studies, a distinction can be made between coronary artery calcification (CAC) and aorto-iliac
calcification, as well as between assessment of calcification prior to and after transplantation.
CAC, expressed as Agatston score by non-contrast enhanced cardiac computed tomography (CT),
demonstrated progression within four years in prevalent kidney transplant recipients and is associated
with myocardial infarction and mortality [14–18]. Aorto-iliac calcification, by plain pelvic X-ray, dual
X-ray absorptiometry, or semi-quantitative CT assessment, was associated with inferior overall patient
survival [12,19–24].
To date, CT imaging of the aorto-iliac vessels prior to kidney transplantation is primarily performed
for surgical planning, while the available imaging data are not widely used for cardiovascular risk
stratification in clinical practice [25,26]. As the imaging data are available, non-contrast enhanced
CT-based quantification of aortic calcification can be used for cardiovascular risk stratification of
patients screened for kidney transplantation, without the need for additional procedures [27,28].
Here, we present the results of a dual-center cohort study for the quantification of aorto-iliac
calcification prior to kidney transplantation and its association with all-cause mortality, cardiovascular
mortality, and cardiovascular events, using the aorto-iliac calcium score (CaScore)—an adapted
Agatston score.
2. Methods
2.1. Subjects and Study Design
Patients referred for a non-contrast enhanced CT-procedure, as part of the screening of high-risk
patients prior to kidney transplantation, were included in a dual-center cohort study (University
Medical Center Groningen and Erasmus MC University Medical Center, The Netherlands). In line
with the pre-transplant screening protocol in both transplant centers, a CT-procedure was required for
transplant screening if either of the following were present: age > 50 years, dialysis vintage > 2 years,
a history of PAD or signs and/or symptoms of PAD, diabetes mellitus, or prior surgery in the iliac fossa.
Patients were referred for pre-transplant cardiac evaluation if the following were present: symptoms
and signs of cardiac disease, a history of cardiac disease, reduced exercise tolerance, PAD, or diabetes
mellitus. All adult patients undergoing kidney transplantation between January 2005 to December
2018, in which a CT-procedure was performed within three years prior to transplantation, were
considered eligible. Transplant-related data was extracted from the Dutch Organ Transplant Registry
and the electronic patient records were screened for baseline and follow-up variables. The study was
performed in line with the Declaration of Helsinki and the principles outlined in the Declaration of
Istanbul on Organ Trafficking and Transplant Tourism. The Medical Ethical Committee gave approval
(University Medical Center Groningen 2017/523) for this dual-center cohort study.
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2.2. Outcome Measures and Clinical Variables
The primary outcome measure of this study was all-cause mortality and the secondary outcome
measures were cardiovascular mortality and cardiovascular events (including cardiovascular mortality
and events). Cardiovascular events were defined as MI (International Statistical Classification of
Diseases and Related Health Problems (ICD)-10: I21), CVA (ICD I60-I66), TIA (ICD-10 G45), or new
onset PAD (ICD-10 I73) Fontaine III or IV. Cardiovascular mortality was defined as death due to a
cardiovascular event or heart failure (ICD-10 I50). Baseline characteristics consisted of the following
covariables at time of transplantation: gender, age, diabetes mellitus (fasting glucose ≥ 7.0 mmol/L,
casual plasma glucose ≥ 11.1 mmol/L + diabetes symptoms, or glucose tolerance test with 2-h plasma
glucose ≥ 11.1 mmol/L), Body Mass Index (BMI in kg/m2), smoking status (non, former, current),
total cholesterol level (mmol/L), hypercholesterolemia (total cholesterol level > 5.2 mmol/L or use of
lipid lower medication), systolic and diastolic blood pressure (mmHg), and use of antihypertensive
medication. History of cardiovascular disease consisted of MI, CVA, TIA, or PAD. Comorbidities
were scored using the Charlson Comorbidity Index and the 10-year risk for MI was estimated
with the Framingham score [8,29]. Transplant-related data consisted of date of transplantation,
type of donation (living-donation, donation after circulatory death, and donation after brain death),
number of previous transplantations, type of dialysis (pre-emptive, hemodialysis, or peritoneal
dialysis), and dialysis vintage pre-transplantation. Data at one-year post-transplant consisted of
estimated-Glomerular Filtration Rate (eGFR), calcium, phosphate, albumin, parathyroid hormone
(PTH), and use of calcineurin inhibitors (cyclosporin or tacrolimus).
2.3. Quantification of Aorto-iliac Calcification
Non-contrast enhanced CT images of the aorto-iliac trajectory were extracted from the imaging
databases of both hospitals. Quantification of aorto-iliac calcification was performed for three vascular
segments, being the abdominal aorta inferior of the renal arteries, the common iliac artery, and the
external iliac artery on the side of the subsequent transplant, by an examiner blinded for the patients’
medical details (Figure 1).
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The selected areas of calcification were reviewed on the axial, sagittal, and coronals views,
and adjusted if necessary [28]. Using the syngo.CT CaScoring software (Siemens Healthineers,
Erlangen, Germany), with the standard calcification threshold of 130 Hounsfield Units (HU), the
Agatston score adapted for the aorto-iliac trajectory (aorto-iliac CaScore) was obtained for the three
segments [27].
2.4. Statistical Analysis
Based on the aorto-iliac CaScore, patients were stratified into tertiles of equal size: low CaScore
(0–859 HU), medium CaScore (860–5600 HU), and high CaScore (>5600 HU). The data are presented as
mean (standard deviation, (SD)) in case of normal distribution, median (interquartile range, (IQR)) for
skewed data, and number (percentage, %) for categorical data, for the full cohort and the aorto-iliac
CaScore tertiles. Tertiles were compared using a chi-square test or one-way analysis of variance.
The median (IQR) time of follow-up was calculated with the reversed Kaplan-Meier method, with the
date of transplantation as the start of the follow-up. The cumulative overall, event-free survival, and
cardiovascular survival were calculated using Kaplan-Meier survival curves, comparing aorto-iliac
CaScore tertiles with Log-rank testing. Univariable and multivariable Cox proportional hazards
regression analysis were used to evaluate the association of the aorto-iliac CaScore, as a categorical
and continuous variable, with all-cause mortality, cardiovascular events, and cardiovascular mortality
(Tables S1–S3). Additional survival analysis was performed for time between transplantation and death
with a functioning graft (censored for return to dialysis and re-transplantation). To avoid overfitting of
the multivariable model with the a priori selected covariables, the results are presented in six steps,
as presented in Table 4. Additional analyses of the interaction with covariables was performed by
univariable subgroup analysis and analysis of interaction terms for aorto-iliac CaScore (continuous) and
all-cause mortality, with groups based on the mean or median for continuous variables. The p-values of
interaction terms were considered significant when <0.05 (Keyzer et al.) or <0.20 (Ramos et al.) [11,30].
Skewed variables were transformed to the natural log (log(x + 1)) for the regression analyses and
results are presented as hazard ratio (HR) and corresponding 95% confidence interval (95% CI).
The additional discriminative capacity of the aorto-iliac CaScore compared to a basic model (gender
and age), the Charlson Comorbidity Index, and the Framingham score was assessed using C-statistics
(Harrell’s concordance index), a change in C-statistics, and the integrated discrimination improvement
(IDI). The IDI is a statistical method to describe the predictive performance of biomarkers in extensive
regression models, by comparing an initial model with a model including this new biomarker [31].
A p-value of <0.05 was considered statistically significant. Statistical analyses were performed with R:
A Language and Environment for Statistical Computing, version 1.0.153 for Mac (R Foundation for
Statistical Computing, Vienna, Austria).
3. Results
3.1. Study Population
This dual-center cohort consisted of 547 kidney transplant recipients, with a mean time between
CT and transplantation of 0.91 (0.72) years. In this cohort, 336 (61.4%) patients were male, the median
age at time of transplantation was 60 (51, 68) years, 173 (31.6%) patients had diabetes mellitus, and 350
(64.0%) were on dialysis. Additional baseline characteristics are summarized in Table 1, variables at
one-year post-transplant are summarized in Table 2.
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Table 1. Patient characteristics.
Variables Total (n = 547) Low (n = 183) Medium (n = 182) High (n = 182) p-Value
Male gender a 336 (61.4) 98 (53.6) 108 (57.8) 131 (72.0) 0.001 d
Age, years c 60 (51, 68) 48 (39, 56) 62 (55, 68) 66 (60, 71) <0.001 e
Diabetes mellitus a 173 (31.6) 56 (30.6) 61 (33.5) 56 (30.8) 0.798 d
Body Mass Index, kg/m2 b 26.8 (4.7) 26.0 (5.1) 27.7 (4.6) 26.7 (4.1) 0.002 e
Smoker a <0.001 d
Non 154 (28.2) 74 (40.4) 45 (24.7) 35 (19.2)
Former 332 (60.7) 89 (48.6) 117 (64.3) 126 (69.2)
Current 61 (11.2) 20 (10.9) 20 (11.0) 21 (11.5)
Total cholesterol, mmol/L b 4.7 (1.3) 4.7 (1.2) 4.8 (1.5) 4.5 (1.2) 0.066 e
Hypercholesterolemia a 153 (28.0) 37 (20.2) 59 (32.4) 57 (31.3) 0.016 d
Systolic blood pressure, mmHg b 145 (22) 141 (20) 145 (22) 148 (24) 0.014 e
Diastolic blood pressure, mmHg b 80 (14) 82 (13) 80 (13) 78 (14) 0.018 e
Use of antihypertensive medication a 439 (80.3) 132 (72.1) 150 (82.4) 157 (86.3) 0.002 d
Type of donation a 0.200 d
Living-donation 301 (55.0) 110 (60.1) 105 (57.7) 86 (47.3)
Donation after circulatory death 128 (23.4) 39 (21.3) 36 (19.8) 53 (29.1)
Donation after brain death 118 (21.6) 34 (18.6) 41 (22.5) 43 (23.6)
Previous transplants a 0.161 d
Non 514 (94.0) 167 (93.3) 176 (96.7) 171 (94.0)
One 22 (4.0) 10 (5.5) 4 (2.2) 8 (4.4)
Two 11 (2.0) 6 (3.3) 2 (1.1) 3 (1.6)
Type of dialysis a 0.196 d
Pre-emptive 197 (36.0) 71 (38.8) 71 (39.0) 55 (30.2)
Hemodialysis 250 (45.7) 77 (42.1) 85 (46.7) 88 (48.4)
Peritoneal dialysis 100 (18.3) 36 (19.1) 26 (14.3) 39 (21.4)
Dialysis vintage pre-transplantation,
months c 12 (0, 28) 10 (0, 23) 12 (0, 29) 16 (0, 33) 0.017
f
History of MI a 82 (15.0) 9 (4.9) 30 (16.5) 43 (23.6) <0.001d
History of CVA a 40 (7.3) 7 (3.8) 11 (6.0) 22 (12.1) 0.007d
History of TIA a 23 (4.2) 4 (2.2) 11 (6.0) 8 (4.4) 0.183 d
History of PAD a 78 (14.3) 18 (9.8) 24 (13.2) 36 (19.8) 0.022 d
Charlson Comorbidity Index b 6.4 (2.5) 5.1 (2.0) 6.3 (1.9) 7.7 (2.7) <0.001 e
Framingham score, % c 9.6 (3.4, 18.8) 3.5 (0.6, 9.5) 10.2 (4.1, 20.2) 16.6 (9.4, 23.8) <0.001 f
MI = myocardial infarction; CVA = cerebrovascular accident; TIA = transient ischemic attack; PAD = peripheral artery
disease; a number (%); b mean ± standard deviation (SD); c median (interquartile range); d p-value by chi-square test;
e p-value by One-way ANOVA; f p-value by Kruskal-Wallis test; p-values in bold indicate statistical significance.
Table 2. One-year post-transplant variables.
Variables Total (n = 547) Low (n = 183) Medium (n = 182) High (n = 182) p-Value
Laboratory values a
eGFR b 51.3 (20.6) 55.9 (22.2) 50.2 (18.1) 47.68 (20.82) 0.001 e
Calcium, mmol/L b 2.43 (0.14) 2.40 (0.14) 2.45 (0.13) 2.45 (0.14) 0.001 e
Phosphate, mmol/L b 0.93 (0.21) 0.94 (0.23) 0.95 (0.19) 0.89 (0.19) 0.014 e
Albumin, g/L b 43.3 (3.1) 43.2 (3.4) 43.6 (2.9) 43.0 (3.0) 0.237 e
PTH, pmol/L c 10.4 (7.4, 15.6) 9.4 (6.5, 12.8) 10.6 (7.8, 16.3) 11.6 (8.0, 16.4) 0.020 f
CNI d 535 (97.8) 178 (97.3) 179 (98.4) 178 (97.8) 0.779 g
Ciclosporin d 42 (7.7) 16 (8.7) 13 (7.1) 13 (7.1) 0.803 g
Tacrolimus d 494 (90.3) 163 (89.1) 166 (91.2) 165 (90.7) 0.773 g
eGFR = estimated-Glomerular Filtration Rate, eGFR–CKD-EPI (mL/min per 1.73 m2); PTH = parathyroid hormone;
CNI = calcineurin inhibitors; a one-year post-transplant data available for 462 patients; b mean ± standard deviation
(SD); c median (interquartile range); d number (%); e p-value by student-t test; f p-value by Mann-Whitney U test; g
p-value by chi-square test; p-values in bold indicate statistical significance.
3.2. Aorto-Iliac CaScore and All-Cause Mortality
After a median follow-up of 3.1 (1.4, 5.2) years after transplantation, 80 (14.7%) patients had died
(Table 3). The Kaplan-Meier survival curve for overall survival showed a significant difference between
the tertiles (p < 0.0001) (Figure 2).
In univariable Cox regression analysis, the continuous CaScore was significantly associated with
all-cause mortality (HR 2.02, 95% CI 1.49–2.56, p < 0.0001), with consistent HRs in the subgroup
analysis (Table 4 and Figure 3). Based on the p-value cut-off by Keyzer et al. (<0.05), no significant
interaction terms were found. With the cut-off by Ramos et al. (<0.20), the variables age (p = 0.191) and
diabetes mellitus (p = 0.141) showed a significant interaction. In multivariable Cox regression analysis,
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the association between the CaScore (continuous) and all-cause mortality remained significant after
adjustment in six models, with HR 1.53 (95% CI 1.14–2.06, p = 0.005) in model 5 and HR 1.72 (95% CI
1.22–2.43, p = 0.002) in model 6. A considerably higher HR was observed for the high CaScore (HR
2.59, 95% CI 1.22–5.51) compared to the medium CaScore (HR 1.27, 95% CI 0.60–2.66), with the low
CaScore as reference, with P(trend) = 0.004 (model 5) (Table 4). When censoring patients with graft
failure, the association between the CaScore (continuous) and all-cause mortality (n = 47) remained
significant, with HR 2.32 (95% CI 1.52–3.55, p < 0.0001) after adjustment in five models.
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Table 3. Number (%) of cardiovascular events and deaths.
Total
(n = 547)
Low
(n = 183)
Medium
(n = 182)
High
(n = 182) p-Value
Median follow-up, years 3.1 (1.4, 5.2) 3.6 (2.0, 6.0) 2.6 (1.3, 4.9) 2.7 (1.2, 4.2) -
Mortality
All-cause 80 (14.7) 14 (7.7) 22 (12.1) 44 (24.3) <0.001
Cardiovascular 32 (5.9) 4 (2.2) 10 (5.5) 18 (9.9) 0.007
Cardiovascular events
MI 46 (8.4) 7 (3.8) 17 (9.3) 22 (12.1) 0.015
CVA 16 (2.9) 6 (3.3) 7 (3.8) 3 (1.6) 0.434
TIA 2 (0.4) 0 (0.0) 0 (0.0) 2 (1.1) 0.134
PAD 30 (5.7) 7 (3.8) 9 (4.9) 15 (8.2) 0.166
Combined 84 (15.5) 18 (9.8) 30 (16.5) 36 (19.8) 0.027
Median follow-up after transplantation (interquartile range); cardiovascular events and deaths presented as numbers
(%), p-value by chi-square test MI = myocardial infarction; CVA = cerebrovascular accident; TIA = transient ischemic
attack; PAD = new onset peripheral artery disease, Fontaine III or IV; p-values in bold indicate statistical significance.
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Table 4. Multivariable adjusted associations of CaScore with all-cause mortality, cardiovascular events,
and cardiovascular mortality.
Low Medium High Continuous
Hazard Ratio Hazard Ratio 95% CI Hazard Ratio 95% CI P (Trend) Value Hazard Ratio 95% CI p-Value
All-cause mortality
Univariate 1.0 (Ref) 2.12 1.08–4.15 5.22 2.84–9.58 <0.0001 2.02 1.59–2.56 <0.0001
Model 1 1.0 (Ref) 2.20 1.12–4.32 5.45 2.94–10.07 <0.0001 2.02 1.60–2.56 <0.0001
Model 2 1.0 (Ref) 1.61 0.80–3.25 3.40 1.69–6.85 <0.001 1.72 1.31–2.28 <0.001
Model 3 1.0 (Ref) 1.39 0.67–2.88 3.31 1.60–6.87 <0.001 1.75 1.31–2.33 <0.001
Model 4 1.0 (Ref) 1.28 0.61–2.70 2.84 1.34–6.00 0.002 1.59 1.19–2.14 0.002
Model 5 1.0 (Ref) 1.27 0.60–2.66 2.59 1.22–5.51 0.006 1.53 1.14–2.06 0.005
Model 6 1.0 (Ref) 1.50 0.64–3.51 3.12 1.34–7.26 0.006 1.72 1.22–2.43 0.002
Cardiovascular mortality
Univariate 1.0 (Ref) 3.42 1.07–10.91 7.86 2.63–23.47 <0.0001 2.27 1.55–3.34 <0.0001
Model 1 1.0 (Ref) 3.45 1.08–11.05 7.69 2.55–23.14 <0.0001 2.24 1.53–3.29 <0.0001
Model 2 1.0 (Ref) 2.40 0.72–8.00 4.66 1.38–15.74 0.009 1.94 1.24–3.04 0.004
Model 3 1.0 (Ref) 1.91 0.56–6.59 4.32 1.22–15.38 0.014 1.92 1.19–3.09 0.007
Model 4 1.0 (Ref) 1.65 0.47–5.74 4.40 1.19–16.24 0.013 2.03 1.20–3.42 0.008
Model 5 1.0 (Ref) 1.64 0.46–5.76 4.46 1.19–16.71 0.014 2.04 1.20–3.45 0.008
Model 6 1.0 (Ref) 2.30 0.64–8.32 55.67 1.68–8.32 0.004 2.13 1.32–3.43 0.002
Cardiovascular events
Univariate 1.0 (Ref) 2.13 1.19–3.84 2.86 1.62–5.08 <0.001 1.56 1.25–1.95 <0.0001
Model 1 1.0 (Ref) 2.20 1.22–3.98 2.61 1.46–4.64 <0.001 1.60 1.28–1.99 <0.0001
Model 2 1.0 (Ref) 1.88 1.00–3.53 2.45 1.25–4.81 0.010 1.48 1.13–1.93 0.004
Model 3 1.0 (Ref) 1.69 0.89–3.20 2.58 1.20–4.77 0.013 1.48 1.12–1.94 0.005
Model 4 1.0 (Ref) 1.48 0.76–2.88 2.13 1.05–4.35 0.034 1.39 1.04–1.85 0.025
Model 5 1.0 (Ref) 1.47 0.76–2.85 1.98 0.97–4.07 0.060 1.35 1.01–1.80 0.042
Model 6 1.0 (Ref) 1.47 0.76–2.87 2.17 1.08–4.37 0.028 1.45 1.09–1.92 0.010
Data are presented as hazard ratio and 95% confidence interval (CI) for the tertiles (low, medium, high) and the
continuous (natural log transformed) CaScore outcome; p-values in bold indicate statistical significance. Model 1:
adjusted for transplant center and time between computed tomography and transplantation; Model 2: adjusted for
model 1 plus age at time of transplantation, and gender; Model 3: adjusted for model 2 plus BMI, total cholesterol
level, diabetes mellitus, smoking status, and systolic blood pressure; Model 4: adjusted for model 3 plus type
of dialysis (pre-emptive, hemodialysis, peritoneal dialysis), dialysis vintage pre-transplantation, and number of
previous transplantations; Model 5: adjusted for model 4 plus Charlson Comorbidity Index; Model 6: adjusted for
model 2 plus one year-post transplant variables (eGFR, calcium, phosphate, albumin, PTH).
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3.3. Aorto-iliac CaScore and Cardiovascular Mortality
During the follow-up period, in 32 (40.0%) out of the 80 patients who died, mortality was due to
cardiovascular causes (Table 3). For the remaining patients who died: 17 (21.2%) out of 80 died due
to infection, 15 (18.8%) due to an oncologic cause, three (3.8%) due to pulmonary disease, and for 13
(16.2%), the cause of death could not be established. The Kaplan-Meier survival curve for cardiovascular
survival showed a significant difference between the tertiles (p < 0.0001) (Figure 4).
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Figure 4. Kaplan-Meier curve for (A) cardiovascular survival and (B) cardiovascular event-free
survival for the low aorto-iliac CaScore tertile, the medium CaScore tertile, and the high CaScore tertile.
The cardiovascular survival at the median follow-up time was 98.5% (95% CI 96.4–100.0) in the low,
96.3% (95 CI 92.8–99.9) in the medium, and 86.4% (95% CI 79.5–94.0) in the high CaScore tertile.
The cardiovascular event-free survival at the median follow-up time was 89.3% (95% CI 84.6–94.4) in the
low, 81.0% (95 CI 74.2–88.5) in the mediu , and 75.2% (95% CI 67.0–85.5) in the high CaScore tertile.
In univariable Cox regression analysis, a significant association with cardiovascular mortality
was obse ved for the con inuous CaScore (HR 2.27, 95% CI 1.55–3.34, p < 0.0001). In multivariable
Cox regression analysis, the association between the CaScore and cardiovascular mortality remained
significant after adjustment in six models, HR 2.04 (95% CI 1.20–3.45, p = 0.008) (continuous) in model
5 and HR 2.13 (95% CI 1.32–3.43, p = 0.002) in model 6. A considerably higher HR was observed for
the high CaScore (HR 4.46, 95% CI 1.19–16.71) compared to the medium CaScore (HR 1.64, 95% CI
0.46–5.76), with the low CaScore as reference, with P(trend) = 0.014 (model 5) (Table 4).
3.4. Aorto-Iliac CaScore and Cardiovascular Events
During the follow-up period, a total of 84 (15.5%) patients had one or more cardiovascular events,
as described in detail in Table 3. The Kaplan-Meier survival curve for cardiovascular event-free survival
showed a significant difference between the tertiles (p < 0.001) (Figure 4).
In univariable Cox regression analysis, a significant association with cardiovascular events was
observed for the continuous CaScore (HR 1.56, 95% CI 1.25–1.95, p < 0.0001). In multivariable Cox
regression analysis, the association between the CaScore and cardiovascular events remained significant
after adjustment in six models, HR 1.35 (95% CI 1.01–1.80, p = 0.042) (continuous) in model 5 and HR
1.45 (95% CI 1.09–1.92, p = 0.010) in model 6. No significant increase in HR was observed for the high
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CaScore (HR 1.98, 95% CI 0.97–4.07) compared to the medium CaScore (HR 1.47, 95% CI 0.76–2.85),
with the low CaScore as reference, with P(trend) = 0.060 (model 6) (Table 4).
3.5. Discriminative Capacity of the Aorto-iliac CaScore
The aorto-iliac CaScore alone had a C-statistic of 0.66 (95% CI 0.49-0.72) for all-cause mortality.
When added to a basic model of gender and age, a significant improvement of the c-statistic (0.07, 95%
CI 0.01–0.14, p = 0.042) and a positive and significant IDI (4.1%, p < 0.0001) were observed. Addition
of the CaScore to the Charlson Comorbidity Index and the Framingham score, resulted in c-statistics
of 0.75 (95% CI 0.67–0.83) and 0.76 (95% CI 0.69–0.83), respectively. The improvement in c-statistics
were not significant, whereas the IDI’s were positive and significant for the addition of the CaScore to
the Charlson Comorbidity Index (IDI 4.2, p < 0.0001) and the Framingham score (IDI 2.5, p < 0.001)
(Table S4). C-statistics of the CaScore alone for cardiovascular mortality and cardiovascular events
were 0.72 (95% CI 0.63–0.81) and 0.58 (95% CI 0.52–0.64), respectively. Changes in c-statistics and IDI’s
for these outcome measures are presented in Table S4.
4. Discussion
Non-contrast enhanced CT-based quantification of the aorto-iliac vessels during screening prior
to kidney transplantation, as an adapted Agatston score, is a novel approach in transplant medicine.
In the kidney transplant recipient cohort presented, the aorto-iliac CaScore showed to be associated
with all-cause and cardiovascular mortality, and cardiovascular events after adjustment for traditional
and transplant candidate-specific risk factors. The identified association was consistent in subgroup
and interaction analyses, and the CaScore showed to have a significant discriminative capacity for
all-cause and cardiovascular mortality.
The baseline differences, as compared for the aorto-iliac CaScore tertiles, are in line with previous
studies on cardiovascular risk stratification prior to kidney transplantation [2]. The traditional risk
factors, i.e., male gender, age, BMI, current or former smoker, hypercholesterolemia, and hypertension,
and the transplant candidate-specific risk factor dialysis vintage pre-transplantation, were more
prevalent in the medium and high CaScore tertiles. To note, there were no differences between the
tertiles regarding diabetes mellitus prior to transplantation. The relatively high Charlson Comorbidity
Index pointed towards more comorbidities and the Framingham score showed more expected
cardiovascular events in the medium and high CaScore tertiles. The incidence of cardiovascular events
was high (n = 84, 15.5%) compared to previously published outcomes of kidney transplant recipients
in the Netherlands (8.5–11%, in 5.4 and 7 years, respectively), which was expected since the indication
for a pre-transplant CT-scan was defined by cardiovascular risk factors [12,32].
To establish the clinical relevance of the aorto-iliac CaScore, a comparison was made with
clinical variables available at the time of screening prior to transplantation. The discriminative
capacity of the Charlson Comorbidity Index and Framingham score for all-cause and cardiovascular
mortality significantly increased when the CaScore was added. The c-statistics and IDI’s of the
CaScore for cardiovascular events were considerably lower compared to those for all-cause and
cardiovascular mortality.
The quantification technique for vascular calcification is considered to be reproducible and reliable,
with an interobserver agreement of ≥0.99 and an inter-scanner agreement of ≥0.97 [33,34]. In this study
we focused on the total calcium volume in the aorto-iliac trajectory; the advantages of this approach
are the quantification after non-contrast enhanced CT procedures and the use of CT procedures with
varying slice-thicknesses [27]. In the general population, application of this technique resulted in a
significant difference in five-year cardiovascular event-free survival between the quartiles of abdominal
aorta calcification, outperforming the Framingham score (area under the curve of 0.76 versus 0.64,
p = 0.013) [28].
Two relatively small studies focused on non-contrast enhanced aorto-iliac CT prior to kidney
transplantation, the first (n = 131) with a 14-point visual grading scale and the second with quartiles of
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calcification, demonstrating correlations with surgical complexity and cardiovascular surgery during
follow-up [23,24]. In contrast to the independent association identified in the current study, the two
earlier studies did not find significant associations with all-cause mortality analyses, in cohorts with 21
and four events, respectively. The results of a more recent study, focusing on aorto-iliac stenosis on
contrast-enhanced CT prior to transplantation and all-cause mortality, were in line with our findings
for all-cause mortality [22].
The literature on abdominal aorta calcification (AAC) assessment by plain pelvic X-ray or dual
X-ray absorptiometry, using visual grading scales, is more extensive [13]. Studies evaluating this
method showed results similar to our findings, with significant associations of a high-AAC with
all-cause mortality and cardiovascular events in multivariable Cox regression analyses [12,20,21].
Timing of the imaging procedure in previous studies is an important difference compared with the
current study, as imaging procedures were performed after transplantation and at the physician’s
discretion, instead of CT procedures during the screening prior to transplantation.
For CAC prior to and after kidney transplantation, identified by non-contrast CT, several studies
have shown the association with cardiovascular events and mortality [17,18]. The first prospective
study showing the association of CAC after transplantation and cardiovascular events is from Nguyen
et al., with a mean follow-up of 2.3 years and a total of 31 events [17]. In a small study (n = 112) with
asymptomatic transplant recipients, Roe et al. showed that laboratory markers of inflammation are
associated with the severity of CAC [18].
To our knowledge, this is the largest kidney transplant recipient cohort with CT imaging prior to
transplantation available for re-evaluation. Strengths of this study include the median follow-up of 3.1
years, the representative case-mix of pre-emptive (36.0%) and dialysis-dependent (64.0%) patients,
and the relatively large number of outcome measures studied for all-cause mortality, cardiovascular
mortality, and cardiovascular events, compared to earlier studies. Additionally, the quantification
technique for vascular calcification is considered to be reproducible and reliable, with an interobserver
agreement of ≥0.99 and an inter-scanner agreement of ≥0.97 [33]. For the number of included variables
in the multivariable analyses, we followed the recommendation by Vittinghoff and McCulloch of 5–9
events per predictor variable [35]. This recommendation could be followed for the outcome measures
all-cause mortality and cardiovascular events; however, there is a risk for overfitting in model 4 and
model 5 with the outcome measure cardiovascular mortality. The main limitation of this study is the
selection of patients based on the availability of CT images prior to transplantation, resulting in a
cohort of patients with a relatively high age at transplantation (median 60 years), more comorbidities
(mean Charlson Comorbidity Index of 6.4), and a subsequent higher mortality risk. While the Charlson
Comorbidity Index was high compared to a previously published Dutch kidney transplant cohort,
with a mean of 2.8 (1.0), the median Framingham score of 9.6 (3.4, 18.8) was comparable to earlier
studies [8,36]. The in- and exclusion criteria limit conclusions regarding the assessment of patient’s
suitability for transplantation, as the results of this study cannot be generalized to the overall transplant
candidate population. As the tertiles are based on equal-size groups, the reported CaScore ranges
per tertile are highly population dependent. External validation of these CaScore tertile ranges is
therefore required.
5. Conclusions
In conclusion, in this dual-center kidney transplant recipient cohort, we demonstrated an
independent association of the aorto-iliac CaScore, extracted from commonly performed non-contrast
enhanced CT procedures prior to transplantation, with all-cause mortality, cardiovascular mortality,
and cardiovascular events. These findings can improve the identification of patients at risk for
(cardiovascular) death and those who could potentially benefit from stringent cardiovascular monitoring
to improve their prognosis after transplantation.
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